Related Experiment Video
Updated: Sep 10, 2025
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
8.2K
Ivermectin and gynecologic cancer: What's the data?
Vaidehi Mujumdar1, Marilyn Huang2, Lindsey Chippendale Smith3
1Atrium Health Levine Cancer Institute, 1021 Morehead Drive, Suite 2100, Charlotte, NC 28202, USA.
Gynecologic Oncology Reports
|August 25, 2025
Summary
Ivermectin, approved for parasitic infections, lacks gynecologic cancer treatment data. Researchers caution against its use in gynecologic cancers due to insufficient safety and efficacy evidence.
Area of Science:
- Gynecologic Oncology
- Pharmacology
- Drug Repurposing
Background:
- Ivermectin is FDA-approved for treating parasitic infections like strongyloidiasis and onchocerciasis.
- Existing research on ivermectin's anticancer properties is primarily limited to in vitro cell line studies.
- There is a lack of comprehensive data regarding ivermectin's potential as a gynecologic cancer therapeutic.
Purpose of the Study:
- To evaluate the current evidence base for ivermectin's use in gynecologic cancers.
- To identify the gaps in knowledge regarding ivermectin's safety and efficacy in this patient population.
- To provide a clinical recommendation on ivermectin's utility in gynecologic oncology.
Main Methods:
- Literature review of existing clinical studies and preclinical data on ivermectin in cancer.
- Analysis of FDA-approved indications for ivermectin.
- Assessment of the available evidence specifically for gynecologic cancer applications.
Main Results:
- Current data on ivermectin's efficacy against gynecologic cancers is absent.
- Clinical studies investigating ivermectin for cancer treatment are limited to cell line observations.
- Safety and efficacy of ivermectin in treating gynecologic cancers have not been clinically assessed.
Conclusions:
- The use of ivermectin for treating gynecologic cancers is not supported by current clinical evidence.
- Strong caution is advised against the use of ivermectin in the management of gynecologic cancers.
- Further rigorous clinical trials are necessary to determine any potential role of ivermectin in gynecologic oncology.
Related Concept Videos
01:21Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
01:07Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:28Infertility in Females
401
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
401
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K